Glucotrack and Lōkahi Complete Deal, Creating Lōkahi‑Controlled Public Biopharma Platform

Overview

• The companies have completed their strategic business combination and the combined firm now operates as a publicly listed platform controlled by Lōkahi Therapeutics.
• The combined company secured bridge financing and named E. F. Hutton & Co. as exclusive financial advisor and placement agent to support immediate capital markets activity.
• Lōkahi securityholders received a mix of common stock and convertible preferred stock that is expected to convert into common equity and result in roughly 90% ownership on a fully diluted basis subject to customary stockholder approvals and Nasdaq listing conditions.
• Glucotrack’s implantable continuous blood glucose monitoring program will continue inside a dedicated, wholly owned subsidiary with a portion of transaction proceeds earmarked to fund its development.
• Lōkahi plans to pair its late‑stage development engine with the ai² Futures Lab university sourcing model to identify distressed or shelved clinical assets, and the next milestones to watch are shareholder votes, Nasdaq approvals, and additional financings.